Condition: Oligometastatic Prostate Cancer · Sponsor: Peter MacCallum Cancer Centre, Australia
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
This description comes directly from the study's public registry record.
Gaurav Sharma · +61 3 8559 6830 · Gaurav.Sharma@petermac.org
Annette VanDerHeyden · +61488048792 · Annette.VanDerHeyden@petermac.org
Always discuss trial participation with your own doctor first.
| Royal North Shore | St Leonards, New South Wales, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Sheba Medical Centre | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05560659